Chancery Suit Targets Fee-Shifting Bylaw Enacted Before Ban
A shareholder in StemCells Inc. launched a putative class action Wednesday in Delaware Chancery Court challenging the biopharmaceutical company's fee-shifting bylaw enacted the day the state Senate voted to ban the...To view the full article, register now.
Already a subscriber? Click here to view full article